We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
Read MoreHide Full Article
Intra-Cellular Therapies reported fourth-quarter 2024 loss of 16 cents per share, wider than the Zacks Consensus Estimate of a loss of 5 cents. The company had incurred a loss of 29 cents per share in the year-ago quarter.
Find the latest EPS estimates and surprises on ZacksEarnings Calendar.
Total revenues, comprising only net product sales, came in at $199.2 million, up 51% year over year on the back of strong prescription uptake. The top line beat the Zacks Consensus Estimate of $193 million.
ITCI’s Q4 Results in Detail
Caplyta, the only approved drug in Intra-Cellular’s portfolio, was approved by the FDA in December 2019 for treating schizophrenia in adults. The drug also received the FDA’s approval for treating bipolar depression in December 2021. The label expansion of the drug have boosted sales tremendously.
To maximize the sales potential of Caplyta for its approved indications, the company completed the expansion of its sales force in the third quarter of 2024 for increased accessibility to primary care physicians. Hence, Intra-Cellular hired 150 additional sales representatives. The company has also commenced a second primary care physician sales force expansion in the first quarter of 2025, in anticipation of the potential approval of Caplyta for the adjunctive treatment of major depressive disorder (MDD).
Intra-Cellular did not recognize any grant revenues in the reported quarter.
In the past three months, shares of the company have gained 51.3% against the industry’s 0.5% decline.
Image Source: Zacks Investment Research
Research and development (R&D) expenses surged 38% to $70.3 million from the year-ago quarter’s figure. This uptick was due to higher lumateperone program costs and other pipeline activities.
Selling, general and administrative (SG&A) expenses increased 32% year over year to $137.7 million, driven by marketing and advertising costs.
As of Dec. 31, 2024, ITCI had cash, cash equivalents, restricted cash and investment securities of $1 billion same as that of September end.
ITCI’s Full-Year Results
In 2024, Intra-Cellular’s total revenues amounted to $680.9 million, up 47% over the figure reported in 2023.
ITCI recorded a loss per share of 72 cents in 2024, narrower than the loss of $1.46 reported in 2023. Loss narrowed due to higher revenues.
ITCI’s Key Updates
Last month, Intra-Cellular signed a definitive agreement with Johnson & Johnson (JNJ - Free Report) . Per the terms, JNJ will acquire all outstanding shares of ITCI for $132 per share in cash, aggregating to nearly $14.6 billion. The acquisition will add ITCI’s Caplyta to J&J’s portfolio of marketed drugs. The transaction, expected to be completed later this year, is subject to customary closing conditions and clearance from regulatory authorities.
A regulatory filing seeking the label expansion of Caplyta for the MDD indication is currently under review by the FDA. The submission is supported by positive data from two global phase III studies, Study 501 and Study 502, as well as the long-term safety Study 503.
In the past 30 days, estimates for BioMarin Pharmaceutical’s 2025 earnings per share have increased from $4.01 to $4.05. Estimates for 2026 earnings per share have increased from $5.21 to $5.26 during the same timeframe. In the past three months, BioMarin Pharmaceutical shares have lost 0.4%.
BMRN’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 32.36%.
In the past 30 days, the estimate for Amicus Therapeutics’ 2025 earnings per share has remained constant at 43 cents. The estimate for 2026 earnings per share has deteriorated from 72 cents to 71 cents. In the past three months, shares of Amicus Therapeutics have gained 0.5%.
FOLD’s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 45.42%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
Intra-Cellular Therapies reported fourth-quarter 2024 loss of 16 cents per share, wider than the Zacks Consensus Estimate of a loss of 5 cents. The company had incurred a loss of 29 cents per share in the year-ago quarter.
Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
Total revenues, comprising only net product sales, came in at $199.2 million, up 51% year over year on the back of strong prescription uptake. The top line beat the Zacks Consensus Estimate of $193 million.
ITCI’s Q4 Results in Detail
Caplyta, the only approved drug in Intra-Cellular’s portfolio, was approved by the FDA in December 2019 for treating schizophrenia in adults. The drug also received the FDA’s approval for treating bipolar depression in December 2021. The label expansion of the drug have boosted sales tremendously.
To maximize the sales potential of Caplyta for its approved indications, the company completed the expansion of its sales force in the third quarter of 2024 for increased accessibility to primary care physicians. Hence, Intra-Cellular hired 150 additional sales representatives. The company has also commenced a second primary care physician sales force expansion in the first quarter of 2025, in anticipation of the potential approval of Caplyta for the adjunctive treatment of major depressive disorder (MDD).
Intra-Cellular did not recognize any grant revenues in the reported quarter.
In the past three months, shares of the company have gained 51.3% against the industry’s 0.5% decline.
Image Source: Zacks Investment Research
Research and development (R&D) expenses surged 38% to $70.3 million from the year-ago quarter’s figure. This uptick was due to higher lumateperone program costs and other pipeline activities.
Selling, general and administrative (SG&A) expenses increased 32% year over year to $137.7 million, driven by marketing and advertising costs.
As of Dec. 31, 2024, ITCI had cash, cash equivalents, restricted cash and investment securities of $1 billion same as that of September end.
ITCI’s Full-Year Results
In 2024, Intra-Cellular’s total revenues amounted to $680.9 million, up 47% over the figure reported in 2023.
ITCI recorded a loss per share of 72 cents in 2024, narrower than the loss of $1.46 reported in 2023. Loss narrowed due to higher revenues.
ITCI’s Key Updates
Last month, Intra-Cellular signed a definitive agreement with Johnson & Johnson (JNJ - Free Report) . Per the terms, JNJ will acquire all outstanding shares of ITCI for $132 per share in cash, aggregating to nearly $14.6 billion. The acquisition will add ITCI’s Caplyta to J&J’s portfolio of marketed drugs. The transaction, expected to be completed later this year, is subject to customary closing conditions and clearance from regulatory authorities.
A regulatory filing seeking the label expansion of Caplyta for the MDD indication is currently under review by the FDA. The submission is supported by positive data from two global phase III studies, Study 501 and Study 502, as well as the long-term safety Study 503.
Intra-Cellular Therapies Inc. Price and Consensus
Intra-Cellular Therapies Inc. price-consensus-chart | Intra-Cellular Therapies Inc. Quote
ITCI’s Zacks Rank & Stocks to Consider
Intra-Cellular currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the sector are BioMarin Pharmaceutical (BMRN - Free Report) and Amicus Therapeutics (FOLD - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
In the past 30 days, estimates for BioMarin Pharmaceutical’s 2025 earnings per share have increased from $4.01 to $4.05. Estimates for 2026 earnings per share have increased from $5.21 to $5.26 during the same timeframe. In the past three months, BioMarin Pharmaceutical shares have lost 0.4%.
BMRN’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 32.36%.
In the past 30 days, the estimate for Amicus Therapeutics’ 2025 earnings per share has remained constant at 43 cents. The estimate for 2026 earnings per share has deteriorated from 72 cents to 71 cents. In the past three months, shares of Amicus Therapeutics have gained 0.5%.
FOLD’s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 45.42%.